 HIV
and AIDS Top News Articles |
|
FDA
Approves New Nucleic Acid Test for Screening Donated Blood for HIV-1
Group O and HIV-2 - 1/06/08 |
Switching
from Suppressive Protease Inhibitor-based to Nevirapine
(Viramune)-based Regimens: A Meta-analysis -
1/06/08 |
Reduced
Exercise Tolerance May Signal Silent Cardiac Dysfunction in HIV
Positive People on HAART - 1/06/08 |
Circumcision
Is Associated with Reduced HIV Risk in Heterosexual African-American Men, May
also Protect against Human Papillomavirus (HPV)
- 1/06/08 |
 CDC
Releases Updated Estimates of U.S. HIV Transmission Rates
- 12/12/2008 |
 More
Data Demonstrate Similar Efficacy of Abacavir (Ziagen,
Epzicom) and Tenofovir (Viread, Truvada)
- 12/12/2008 |
 CD8
T-cell Response against HIV-infected Cells Remains Strong in Long-term
Non-progressors - 12/12/2008 |
| Advanced
Liver Disease in People with HIV -
12/12/2008 |
 HIV
Positive People Are More Prone to Infection with Methicillin-resistant
Staphylococcus aureus (MRSA) -
12/12/2008 |
 Antiretroviral
Therapy during Primary HIV Infection Offers Little Lasting Benefit
- 12/09/2008 |
| CD4 Cell Count Improves with HAART-especially
Protease Inhibitors Even if Viral Load Is Not Fully Suppressed -
12/09/2008 |
| Do All Racial/ethnic Groups Need HLA-B*5701
Screening before Starting Abacavir? -
12/09/2008 |
 Carraguard
Microbicide Fails to Prevent HIV Infection in South African Study
- 12/09/2008 |
 Inflammatory
Changes May Help Explain Elevated Cardiovascular and
Diabetes Risk in HIV Patients on Antiretroviral Therapy -
12/05/2008 |
 Inflammatory
Blood Vessel Activation Is Enhanced in HIV Positive People
Independent of Antiretroviral Therapy and Lipoatrophy -
12/05/2008 |
| Atherosclerosis,
Coronary Plaques, and Heart Rhythm Changes in People
with HIV - 12/05/2008 |
 Further
Evidence that Sexual Transmission of HIV Is
Much More Likely During Primary and Late-stage Infection -
12/05/2008 |
 American
College of Physicians Recommends Routine HIV Screening
for All Patients - 12/05/2008 |
 Model
Suggests Universal HIV Testing and Treatment
Could Halt Epidemic within 50 Years - 12/02/2008
|
 Late
HIV Diagnosis and Treatment Is Associated with High Death Rate, but
Many Patients Can Achieve Good CD4 Cell Recovery -
12/02/2008 |
| IL-2
May Be Used as Rescue Therapy for People Who Start Antiretroviral Treatment with
a Low CD4 Count - 12/02/2008 |
| CCR5
Antagonist Maraviroc (Selzentry) Receives
Full FDA Approval - 12/02/2008 |
| HAART
Has Clinical Benefits Even if Treatment Is Started Late, CD4 Cell Count
Remains Low, and Viral Load Is Not Fully Suppressed -
11/25/2008 |
| Second-line
Regimens Twice as Likely to Fail as Initial Therapy -
11/25/2008 |
| Success
with Less than 95% Adherence and the Role of Adherence in Treatment
Failure and Emergence of Drug Resistance -
11/25/2008 |
 The
Perpetual Challenge of Emerging Devastating Diseases
- 11/25/2008 |
 New
Analysis Confirms Higher Risk of Non-AIDS-defining Cancers
in HIV Positive People - 11/21/2008
|
 CHER
Trial Shows Prompt Diagnosis and Early Antiretroviral Therapy Can Reduce
Death of HIV-infected Infants - 11/21/2008 |
| People
Who Start HAART with a Higher CD4 Count Are More Likely to Achieve Complete
Immune Recovery - 11/21/2008 |
| Atripla
Users May Be Able to Take Weekend Treatment Breaks -
11/18/2008 |
| Treatment
Interruption May Be Appropriate for Selected Adults and Children with
HIV if CD4 Count is Maintained at a High Level -
11/18/2008 |
| Modern
HAART Is Associated with Better Adherence and Greater Efficacy than
Older Regimens - 11/18/2008 |
| Zinc
Finger Nuclease That Disables CCR5 Gene May Offer Potential New HIV
Treatment Approach - 11/18/2008 |
| Excellent
Response with a PI- and NRTI-sparing Regimen of Raltegravir
(Isentress), Maraviroc (Selzentry), and Etravirine
(Intelence) - 11/14/2008 |
| Adherence,
Pharmacokinetics, and Metabolic Changes in Treatment-naive Patients Receiving
Once-daily or Twice-daily Lopinavir/ritonavir (Kaletra):
Study M05-730 - 11/14/2008 |
| Biomarkers
of Inflammation and Coagulation in Children and Adolescents
with HIV - 11/14/2008 |
 Rosuvastatin
(Crestor) Dramatically Lowers Cardiovascular Risk in Individuals with
Normal Cholesterol but Elevated CRP - 11/14/2008 |
 GlaxoSmithKline
Launches New Patient Assistance Program for
7 Antiretroviral Drugs or Coformulations -
11/14/2008 |
| Studies
Look at Long-term Safety of Tenofovir (Viread/Truvada/Atripla),
including Kidney Toxicity and Bone Loss -
11/11/2008 |
| Should
Antiretroviral Therapy Be Guided By Therapeutic Drug
Monitoring? - 11/11/2008 |
| Experimental
HIV Entry Inhibitor PRO 140 Demonstrates Favorable
Activity Phase 2 Trial - 11/11/2008
|
| Investigational
NNRTI RDEA806 Exhibits Promising Activity
and Has High Barrier to Resistance - 11/11/2008
|
| Race/ethnicity
and Income Impact HIV Treatment Access and Outcomes -
11/07/08 |
| Maraviroc
(Selzentry) Is Associated with Faster and Larger CD4 Cell Gains: MERIT
Trial - 11/07/08 |
| HIV
Positive People on HAART Have an Elevated Risk of Pulmonary
Hypertension - 11/07/08 |
| Experimental
NRTI Elvucitabine Suppresses HIV as Well as
Lamivudine at 48 Weeks - 11/07/08 |
| Risk
of Hospitalization Remains High for 3 Months after Starting HAART
- 11/04/08 |
| Lopinavir/ritonavir
(Kaletra) Monotherapy Produces Sustained HIV Suppression: IMANI-2 and
OK04 Studies - 11/04/08 |
| Fosamprenavir
(Lexiva) Is Equally Effective with a Lower 100 mg Ritonavir
(Norvir) Boosting Dose - 11/04/08 |
| Experimental
HIV Maturation Inhibitor Bevirimat Demonstrates
Good Antiviral Activity and Favorable Safety Profile -
11/04/08 |
 New
Updates to Adult and Adolescent Anti-HIV Treatment Guidelines
- 11/04/08-
11/04/08 |
| Is
HIV Becoming More Virulent? - 10/31/2008 |
| Abacavir/lamivudine
(Epzicom) plus Boosted Atazanavir (Reyataz) Provides Potent Antiviral
Activity at All Viral Load Levels in ARIES Trial; Meta-analysis Favors Tenofovir/emtricitabine
(Truvada) - 10/31/2008 |
| Boosted
Atazanavir (Reyataz) and Lopinavir/ritonavir (Kaletra) Are Both Highly
Effective through 96 Weeks, but Atazanavir Has Better Side Effects Profile: CASTLE
Study - 10/31/2008 |
| Darunavir
(Prezista) Is Safe and Effective in HIV Positive Children and Adolescents
at 48 Weeks: DELPHI Trial - 10/31/2008 |
| Continuous
HAART Associated with Elevated Risk of Bone Loss
in SMART Treatment Interruption Trial - 10/31/2008 |
 Starting
HAART with a CD4 Count of 351-500 Reduces Risk of Death
by 71% - 10/28/2008 |
 Raltegravir
(Isentress) Is as Effective as Efavirenz (Sustiva)
at 48 Weeks in Treatment-naive Patients: STARTMRK Trial
- 10/28/2008 |
| MERIT
Reanalysis with More Sensitive Trofile Test Shows Maraviroc
(Selzentry) Works as well as Efavirenz (Sustiva)
in Patients New to Therapy - 10/28/2008 |
| Long-term
Safety of Investigational CCR5 Antagonist Vicriviroc
in Treatment-experienced Patients - 10/28/2008 |
| Efficacy
and Safety of Boosted Darunavir (Prezista)
Are Comparable to Lopinavir/ritonavir (Kaletra)
at 96 Weeks: ARTEMIS Trial - 10/28/2008 |
 Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Begins this Weekend in Washington, DC -
10/24/08 |
 Darunavir
(Prezista) Receives Full Traditional Approval, Dose Set for Treatment-naive
Patients, Caution Urged for Pregnant Women -
10/24/08 |
 Inflammation
and Coagulation Biomarkers Linked to Higher Risk of Death in Patients
Who Interrupt Antiretroviral Therapy - 10/24/08 |
| Excess
Risk of Opportunistic Diseases and Death Remains
after Reinitiating HAART following Treatment Interruption -
10/24/08 |
| Study
Suggests HIV Could Rebound from a Single T-cell
if Antiretroviral Therapy Is Interrupted -
10/24/08 |
 Drug
Resistance Is More Likely with NNRTIs than with Boosted Protease Inhibitors
- 10/21/08
|
| Emergence
of Drug Resistance Is Associated with Treatment
Failure -
10/21/08 |
 Lowest-ever
CD4 Cell Count Predicts Neurocognitive Impairment
in People with HIV -
10/21/08 |
 Cancer
and Long-term Toxicities in Children Exposed to Antiretroviral Drugs
before Birth -
10/21/08 |
 Researchers
Identify Proteins Associated with Resistance to HIV
Infection in Kenyan Sex Workers -
10/21/08 |
|
